Please login to the form below

alogliptin

This page shows the latest alogliptin news and features for those working in and with pharma, biotech and healthcare.

FDA won't add outcomes data to Januvia label

Those concerns have caused warnings to be imposed on some rival drugs, namely AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin).

Latest news

AZ gets US approval for diabetes combo Qtern

The FDA turned down Qtern with a request for more data 16 months ago, shortly before insisting on new labelling for saxagliptin and Takeda's rival DPP4 inhibitor Nesina (alogliptin) warning
EU clears AZ's FDA-rejected diabetes combination

Since then however, Onglyza and certain other DPP4 inhibitors such as Takeda's Nesina (alogliptin) have been hit by a series of safety warnings from the FDA, including an increased risk
Merck & Co's diabetes drug Januvia cleared by CV safety trial

Earlier this year FDA advisers recommended two DPP-4 inhibitors, AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin), should have their labelling updated to indicate a link to heart failure.
FDA warns of safety concern with SGLT2 inhibitors

In April, an FDA advisory committee voted that labelling for AZ's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin) should be amended to reflect an increase in the risk of hospitalisation
Relief as study finds no cardiovascular risk with Januvia

death. Importantly, the study was designed to specifically look at hospitalisations due to heart failure, which emerged as the safety signal for AZ's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin),

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

Market dynamics, marketing and analytics

Perhaps the surprise of the market is the growth of Vipidia (alogliptin) - a late 5th entrant DPP4.
Pharma deals during April 2014

NDA submission is planned by third quarter of 2014. Forest plans to sell Furiex's royalty rights to alogliptin and Priligy on to Royalty Pharma for about $415m.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

PMHub

Add my company

Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story: ...
Working together to achieve better patient pathways: Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.: How design can lead improvement within Pharma...

Email:
Password:

Please login to the form below

alogliptin

Subscribe to our email news alerts

Quick links